Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Advanced Medical Solutions extends deadline for H.B. Fuller to 2 July

Advanced Medical Solutions has extended the “put up or shut up” deadline for H.B. Fuller to 2 July 2026 at 17:00 London time. The Takeover Panel approved the extension; the original deadline expired today. The parties continue to hold talks, no firm offer has been confirmed, and the AMS board is advising shareholders to take no action for now. » More on de.investing.com
Advanced Medical Solutions invites shareholders to annual general meeting on 17 June

Advanced Medical Solutions has sent its annual report and financial statements for the year ended 31 December 2025, together with the invitation to the annual general meeting, to shareholders. The AGM will be held on 17 June 2026 at 11:00 in the offices of Investec Bank, 30 Gresham Street, London. The annual report, financial statements and proxy form are available in the investor relations section of the company's website. » More on de.investing.com
Advanced Medical Solutions: 2025 annual results in line with guidance with strong Surgical growth

Advanced Medical Solutions reported 2025 revenue of £228.9m and adjusted EBITDA of £49.9m (adjusted EBITDA margin 21.8%), in line with the January update and analyst consensus. The Surgical division grew 36% at constant currency and was a major contributor; Woundcare rose 9% at constant currency. Margins were 24.4% (Surgical) and 13.6% (Woundcare); EPS came in 3% below the FactSet consensus due to higher interest expenses. Synergies from the acquisitions of Peters and Syntacoll are progressing as planned, and the company expects 2026 revenue and EBITDA to be in line with market expectations, with strong cash generation to reduce debt. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Advanced Medical Solutions has already paid €0.0309 in dividends. The last payout was in October 2025.

Financials

In the last quarter, Advanced Medical Solutions had revenue of €134.02m and net profit of -€75.45k

(EUR)	June 2026	YoY
Revenue	134.02m	-
Gross profit	64.69m	-
Net profit	-75.45k	-
EBITDA	30.16m	-

Fundamentals

Metric	Value
Market capitalization	€732.72m
Number of shares	216.4m
52-week high/low	€3.41 - €2.24
Dividends	No
Beta	0.75
P/E ratio	166.18
PEG ratio	-2.78
P/B ratio	2.41
P/S ratio	2.62

Company profile

Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, France, rest of Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand brand; sutures and collagen-based products for the surgical and dental markets under the RESORBA brand; collagens; and laparoscopic device used to fix hernia meshes placed inside the body under the LiquiBand Fix8 brand, as well as internal sealants under the Seal-G/Seal-G MIST brand. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal brand. Advanced Medical Solutions Group plc was incorporated in 1991 and is headquartered in Winsford, the United Kingdom.